Evotec SE
EVONASDAQHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$1.93
−$0.03 · -1.53%
EVO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
47
Fair Value
Momentum
30
Weakening
Sentiment
45
Mixed
Risk resilience
40
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEvotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- DE
- CEO
- Christian Wojczewski
- Listed since
- Feb 5, 2004
- Employees
- 4,553
Market position
Day range
Current $1.93
52-week range
Current $1.93
- Open
- $1.935
- Previous close
- $1.96
- Volume
- 40.87K
- 0.61× average
- Average volume
- 66.47K
- Average daily volume
- Market cap
- 685.61M USD
- Beta
- 1.26
- Market reference 1
- 50-day average
- $2.2986
- -16.04% below average
- 200-day average
- $2.8987
- -33.42% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 960.16M EUR
- P/E (TTM)
- -3.03×
- P/B (TTM)
- 0.9×
- P/S (TTM)
- 0.83×
- EV / EBITDA
- -69.12×
- Earnings yield
- -10.68%
- Free cash flow yield
- -8.46%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 10.49%
- Operating margin
- -17.68%
- Net margin
- -27.47%
- Return on equity
- -12.22%
- Return on assets
- -5.59%
- Return on invested capital
- -7.21%
Financial health
- Debt / equity
- 0.71×
- Current ratio
- 2.07×
- Altman Z-score
- -0.06
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 757.26M EUR | 796.97M EUR | 781.43M EUR | 751.45M EUR | 618.03M EUR |
| Cost of goods sold | 694.6M EUR | 682.09M EUR | 606.38M EUR | 577.38M EUR | 466.49M EUR |
| Gross profit | 62.66M EUR | 114.88M EUR | 175.05M EUR | 174.07M EUR | 151.54M EUR |
| Research and development | 74.33M EUR | 50.86M EUR | 68.53M EUR | 76.64M EUR | 65.7M EUR |
| Selling, general, and administrative | 123.65M EUR | 188.2M EUR | 169.61M EUR | 156.19M EUR | 105.45M EUR |
| Operating expenses | 197.97M EUR | 257.4M EUR | 222.56M EUR | 153.22M EUR | 110.55M EUR |
| Interest income | 4.25M EUR | 2.44M EUR | 9.26M EUR | 8.34M EUR | 2.27M EUR |
| Interest expense | 13.87M EUR | 11.7M EUR | 11.74M EUR | 13.15M EUR | 9.25M EUR |
| Depreciation and amortization | 95.55M EUR | 101.62M EUR | 92.98M EUR | 83.2M EUR | 70.4M EUR |
| Operating income | −135.31M EUR | −142.52M EUR | −47.51M EUR | 20.85M EUR | 41M EUR |
| Net income | −99.43M EUR | −196.08M EUR | −83.91M EUR | −175.66M EUR | 215.51M EUR |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 9%
- 1 beat, 10 misses, 0 met estimates
- Average EPS surprise
- -157.64%
- 11 comparable reports
- Latest EPS result
- -0.17
- Estimate -0.05 · Miss by 275.40%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
EVO news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$0.5412
2018 complete year-6.0% since 2017
$0.576
2,017
$0.5412
2,018
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 11, 2019 | $0.2888Monthly | — | — |
Dividend | Dec 12, 2018 | $0.1804Monthly | — | — |
Dividend | Nov 8, 2018 | $0.1804Monthly | — | — |
Dividend | Oct 10, 2018 | $0.1804Monthly | — | — |
Dividend | Sep 13, 2018 | $0.1804Monthly | — | — |
Dividend | Aug 10, 2018 | $0.1804Monthly | — | — |
Ex-dividend Jan 11, 2019
$0.2888
Monthly
Ex-dividend Dec 12, 2018
$0.1804
Monthly
Ex-dividend Nov 8, 2018
$0.1804
Monthly
Ex-dividend Oct 10, 2018
$0.1804
Monthly
Ex-dividend Sep 13, 2018
$0.1804
Monthly
Ex-dividend Aug 10, 2018
$0.1804
Monthly
EVO peers
ETFs holding EVO
Funds reporting this stock among their holdings, ordered by reported position size.
John Hancock Investments - Multifactor Developed International ETFJHMD315K0.03%971.55M USD0.39%$46.405+0.66%
WisdomTree International Efficient Core FundNTSI227.98K0.05%497.83M USD0.26%$48.38+0.54%
Affinity World Leaders Equity ETFWLDR38.94K0.21%97.04M USD1.05%$47.57+0.83%
Applied Finance IVS International Large ETFIVSI24.27K0.25%6.04M USD0.65%$30.1766+0.65%John Hancock Investments - Multifactor Developed International ETFJHMD- Market value
- 315K
- Weight
- 0.03%
- AUM
- 971.55M USD
- Expense ratio
- 0.39%
- Price / 1D
- $46.405+0.66%
WisdomTree International Efficient Core FundNTSI- Market value
- 227.98K
- Weight
- 0.05%
- AUM
- 497.83M USD
- Expense ratio
- 0.26%
- Price / 1D
- $48.38+0.54%
Affinity World Leaders Equity ETFWLDR- Market value
- 38.94K
- Weight
- 0.21%
- AUM
- 97.04M USD
- Expense ratio
- 1.05%
- Price / 1D
- $47.57+0.83%
Applied Finance IVS International Large ETFIVSI- Market value
- 24.27K
- Weight
- 0.25%
- AUM
- 6.04M USD
- Expense ratio
- 0.65%
- Price / 1D
- $30.1766+0.65%
Continue in GoAI
Research EVOresearch.disclaimer